147 related articles for article (PubMed ID: 9196574)
1. Interferon beta: the current position.
Boothman BR
Br J Hosp Med; 1997 Mar 19-Apr 1; 57(6):277-80. PubMed ID: 9196574
[TBL] [Abstract][Full Text] [Related]
2. Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis.
Schwid SR; Panitch HS
Clin Ther; 2007 Sep; 29(9):2031-48. PubMed ID: 18035202
[TBL] [Abstract][Full Text] [Related]
3. Early treatment.
Comi G
Neurol Sci; 2006 Mar; 27 Suppl 1():S8-12. PubMed ID: 16708191
[TBL] [Abstract][Full Text] [Related]
4. Use of interferon-beta in the treatment of multiple sclerosis.
Derwenskus J; Lublin FD
Adv Neurol; 2006; 98():257-71. PubMed ID: 16400838
[No Abstract] [Full Text] [Related]
5. Treatment of multiple sclerosis with interferon beta 1b.
Dhib-Jalbut S; McFarland HF
Baillieres Clin Neurol; 1997 Oct; 6(3):467-80. PubMed ID: 10101584
[TBL] [Abstract][Full Text] [Related]
6. Clinical effects and tolerability of high-dose, high-frequency recombinant interferon beta-1a in patients with multiple sclerosis: maximizing therapy through long-term adherence.
Boyko AN
Expert Opin Biol Ther; 2010 Apr; 10(4):653-66. PubMed ID: 20218924
[TBL] [Abstract][Full Text] [Related]
7. Multiple sclerosis: interferon beta for some serious forms.
Prescrire Int; 2007 Dec; 16(92):252-7. PubMed ID: 18092425
[TBL] [Abstract][Full Text] [Related]
8. [Treatment of multiple sclerosis with interferons].
Nogales-Gaete J; Arriagada C
Rev Med Chil; 1996 May; 124(5):597-604. PubMed ID: 9035514
[TBL] [Abstract][Full Text] [Related]
9. [Interferon beta-1b in multiple sclerosis--news regarding open questions].
Nervenarzt; 1997 Aug; 68(8 Suppl Interferon):1-4. PubMed ID: 9380220
[No Abstract] [Full Text] [Related]
10. Advancing treatment with interferon beta-1b (Betaferon/Betaseron) in the next decade--thinking beyond the standard dose.
Cook SD
J Neurol; 2003 Dec; 250 Suppl 4():IV15-20. PubMed ID: 14712397
[TBL] [Abstract][Full Text] [Related]
11. Interferon-beta1a treatment for multiple sclerosis.
Sandberg-Wollheim M
Expert Rev Neurother; 2005 Jan; 5(1):25-34. PubMed ID: 15853471
[TBL] [Abstract][Full Text] [Related]
12. Impact of neutralizing antibodies on the clinical efficacy of interferon beta in multiple sclerosis.
Vartanian T; Sölberg Sørensen P; Rice G
J Neurol; 2004 Jun; 251 Suppl 2():II25-30. PubMed ID: 15264109
[TBL] [Abstract][Full Text] [Related]
13. Interferon beta-1A: new preparation. A short-term impact on the course of multiple sclerosis.
Prescrire Int; 1998 Oct; 7(37):142-3. PubMed ID: 10915418
[TBL] [Abstract][Full Text] [Related]
14. [Interferon therapy of multiple sclerosis].
Jensen D
Tidsskr Nor Laegeforen; 1999 Sep; 119(21):3142-5. PubMed ID: 10522481
[TBL] [Abstract][Full Text] [Related]
15. [Immunomodulatory therapy in multiple sclerosis].
Csépány T; Bereczki D
Ideggyogy Sz; 2004 Nov; 57(11-12):401-16. PubMed ID: 15662768
[TBL] [Abstract][Full Text] [Related]
16. [A short history of beta-interferon therapy of multiple sclerosis].
Stock G; Horowski R
Med Klin (Munich); 2001 Sep; 96 Suppl 1():3-9. PubMed ID: 11603113
[TBL] [Abstract][Full Text] [Related]
17. Neutralizing antibodies (NABS) and interferon beta-1b therapy of multiple sclerosis.
Horowski R; Stürzebecher CS; Kapp JF
Funct Neurol; 2001; 16(2):117-28. PubMed ID: 11495417
[No Abstract] [Full Text] [Related]
18. Lessons from randomised direct comparative trials.
Achiron A; Fredrikson S
J Neurol Sci; 2009 Feb; 277 Suppl 1():S19-24. PubMed ID: 19200860
[TBL] [Abstract][Full Text] [Related]
19. Disease-modifying drugs for the early treatment of multiple sclerosis.
Flachenecker P
Expert Rev Neurother; 2004 May; 4(3):455-63. PubMed ID: 15853542
[TBL] [Abstract][Full Text] [Related]
20. Guidelines for early treatment trials in patients presenting with clinical and paraclinical abnormalities which put them at high risk for conversion to multiple sclerosis. European Charcot Foundation Working Group for Treatment Trials.
Mult Scler; 1995; 1 Suppl 1():S55-9. PubMed ID: 9345401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
